Mineishi, S <br/><br/>
Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity.  [electronic resource] 

 -  Bone marrow transplantation  Jun 1999 
 - 1217-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1701793  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Bone Marrow Transplantation<br/>Child<br/>Child, Preschool<br/>Combined Modality Therapy<br/>Cytarabine--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Leukemia--drug therapy<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Transplantation Conditioning